Orakl Oncology SAS

Orakl Oncology develops best-in-class patient-derived tumor avatars (tumoroids) cultivated from real-world patient data. Their platform integrates cutting-edge biology with data analysis to provide biological evidence supporting target validation, biomarker discovery, and combinatorial treatment strategies. This accelerates drug development and empowers strategic decision-making for pharmaceutical and biotech partners aiming to bring more effective cancer therapies to patients.